PHARMACY

TruMedicines launches Kickstarter for Rx adherence app

BY DSN STAFF

SEATTLE — Big data and pharmaceutical tracking and authentication company TruMedicines on Tuesday launched a 40-day Kickstarter campaign for a smartphone app that promotes medication safety.

TruMedicines said the app will help stymy issues responsible for over a million deaths every year and billions of dollars in additional healthcare costs — counterfeit medication and adherence. Particularly with regard to counterfeit medication, TruMedicine’s David Prokop learned that people’s inability to figure out whether a drug is legitimate or not was a problem that needed fixing.

“When I learned about the epidemic of children dying due to counterfeit malaria pills, it became my mission to find a solution,” Prokop said.

The app requires a two-step authentication process — users first scan a QR code on the back of a TruMedicines box, and then take a photo of the pill, comparing it against the companies cloud database of medication. The process verifies where the drug was made, its expiration date and side effects. Designed to be accessible to people who are illiterate or have poor vision, the app provides information verbally and in large font in 52 languages.

Besides the issue of counterfeit medication is ensuring that patients take their medication properly and regularly — something that 90% of diabetes patients and 50% of cancer patients don’t fully do. So the TruMedicines app will send text message notifications to a patient’s family and doctor if a dose is skipped and will incentivize adherence through a rewards program.

“I’m thrilled that TruMedicines not only has the capability to dramatically reduce these avoidable deaths, but it also assists patients with compliance to ensure that medications are taken as prescribed,” Prokop said.

The Kickstarter campaign seeks to secure $150,000 to fund a April 2016 launch.  

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Aurobindo gets OK from FDA for Zyrtec generic

BY David Salazar

DAYTON, N.J. — Aurobindo Pharma Limited announced Tuesday that it had received approval from the Food and Drug Administration for its over-the-counter cetirizine hydrochloride in 5- and 10-mg dosage strengths. The drug is a generic version of Zyrtec.

The cetirizine hydrochloride tablets are indicated for temporarily relieves runny nose, sneezing, itchy, watery eyes and itching of the nose or throat caused by hay fever or other upper respiratory allergies.    

The product has an estimated market size of $264MM for the twelve months ending January 2014, according to IRI.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Advocating pharmacy: A Q&A with NACDS’ Tom O’Donnell

BY DSN STAFF

Leading up to NACDS Total Store Expo, Drug Store News had an opportunity to sit down with Tom O’Donnell, VP federal government affairs at the National Association of Chain Drug Stores, to discuss pharmacist provider status and the latest pro-pharmacy legislative initiatives in the U.S. House and Senate.

DSN: The pharmacy profession and retail pharmacy industry continue to struggle for full provider status recognition, and a fair and standardized reimbursement model for an expanding menu of patient-care services. How would you describe the role of NACDS in advancing those efforts?
Tom O’Donnell: Even as we work to accomplish these goals, it’s worth noting that advocating for this legislation has given pharmacy a tremendous opportunity to build recognition of pharmacy’s value. That already has proven effective. 

For example, when the U.S. House Energy and Commerce Committee considered the 21st Century Cures legislation in June, there was a proposal on the table to help pay for the legislation in a way that would have reduced pharmacy Medicaid reimbursement. Based on the elevated awareness of pharmacy, NACDS successfully made the case that this move would have hurt beneficiary access to medications, and the proposal was dropped.

In addition, we continue to push the proactive legislation that you mentioned. The Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 592/S. 314) has 185 cosponsors in the U.S. House (82 Democrats; 103 Republicans) and 28 Senate cosponsors (16 Democrats; 12 Republicans). Certainly, we would love to see this legislation enacted this year, yet we have prepared for a multiyear campaign to achieve this goal — similar to the approach of the nurses in the late 90s.

NACDS is working as a Steering Committee member of the Patient Access to Pharmacists’ Care Coalition (PAPCC), which is waging a Washington, D.C., advertising campaign and other strategies to help advocate for the legislation.

The Medication Therapy Management Empowerment Act of 2015 (S. 776) also is gaining traction in the Senate with 13 cosponsors (10 Democrats and 3 Republicans). This legislation would allow Medicare Part D beneficiaries to become eligible for MTM services, if they suffer from a single chronic condition that has been shown to respond well to improved medication adherence such as diabetes, cardiovascular disease, COPD and high cholesterol. NACDS is working to gain support for introduction of similar legislation in the U.S. House, again emphasizing the role of pharmacists in advancing patient care.  

DSN: And how would it change the practice and business model of retail pharmacy?
O’Donnell: The provider-status legislation would make available to underserved Medicare patients the services that state laws allow pharmacists to administer. 

Pharmacists are highly educated and trained healthcare professionals who now must earn a doctor of pharmacy degree (Pharm.D.) to graduate — which takes a minimum of six years to complete and reflects the evolution of pharmacy practice to a more patient-centered focus. 

This legislation would reflect this positive advancement of pharmacy practice, and would keep the momentum moving forward in terms of the ability of pharmacists to improve access to healthcare services.

DSN: Briefly, can you describe the basic elements of H.R. 592 v. 314 that impact the role of pharmacists serving the medically underserved?
O’Donnell: H.R. 592/S. 314 would amend The Social Security Act of 1935 to enable pharmacists to provide to Medicare patients in underserved communities services that pharmacists already are providing for other patients under state law.  

Specifically, Medicare patients would have enhanced access to pharmacists’ expertise and pharmacy services, including immunizations, diabetes screenings and self-management education, cardiovascular screenings and behavioral therapy — in states in which pharmacists are allowed to provide these services.

These bills would enable all licensed pharmacists to care for Medicare patients to the full extent of state scope of practice laws, elevating pharmacists’ ability to improve patient health.  

DSN: H.R. 592/S. 314 seems to be the primary focus right now for NACDS’ lobbying efforts on behalf of legislation to grant pharmacists full provider status. But NACDS is also weighing in on other issues that could impact retail pharmacy practice and business. Can you describe some of those other areas of focus?
O’Donnell: In addition to the provider status legislation, there are two other pieces of legislation that are important to highlight.

NACDS has worked with Sen. Pat Roberts, R-Kan., and Sen. Jeanne Shaheen, D-N.H., to expand beneficiary eligibility for MTM services.  As previously discussed, their legislation — S. 776, the Medication Therapy Management Empowerment Act of 2015 — would provide access to MTM services for beneficiaries with diabetes, cardiovascular disease, COPD and high cholesterol. 

NACDS is also working on efforts in the U.S. House to increase medication adherence and expand MTM criteria, including participating in the efforts of the House Energy and Commerce Committee’s “Better Use of Medicines” Working Group to draft medication adherence legislation.  

NACDS has also been helping to advance legislation to fight prescription drug abuse and help preserve patient access to needed pain medication. The “Ensuring Patient Access and Effective Drug Enforcement Act of 2015” (H.R. 471/S. 483) was introduced in the U.S. House by Rep. Tom Marino, R-Pa., and in the U.S. Senate by Sen. Orrin Hatch, R-Utah.  

This legislation would promote a comprehensive, collaborative approach to preventing prescription drug diversion and abuse bringing together all stakeholders — law enforcement, patient groups, pharmacy and government agencies — to work toward a solution.  

H.R. 471 passed the U.S. House by voice vote earlier in the year, so it’s on to the Senate.

DSN: The NACDS RxImpact Day has been an effective way to tell pharmacy’s story on Capitol Hill, but it occurs one day each year. What should pharmacy operators around the country be doing throughout this year to elevate the status of pharmacists nationally and in their own communities — and to improve chances for passage of bills like H.R. 592?
O’Donnell: There is no doubt that NACDS’ grassroots advocacy program — NACDS RxImpact — can move mountains in advancing pro-patient, pro-pharmacy legislative initiatives. And it is a process that takes year-round diligence and commitment to deliver results.  

The program empowers pharmacists, pharmacy students, pharmacy school faculty, pharmacy technicians and other pharmacy personnel and patients to engage in the political process.  

The NACDS RxImpact program has several components, including the annual NACDS RxImpact Day on Capitol Hill; the Key Contact program, designed to build relationships with elected officials; training programs for pharmacy students; and more.

The most interactive opportunity for lawmakers to understand the value of pharmacists’ role in advancing patient health is the NACDS RxImpact Pharmacy Tour program. Through this program, lawmakers can see firsthand what pharmacists can do to help patients improve their health and manage chronic conditions.  

To learn more about the NACDS RxImpact Pharmacy Tour Program and other grassroots advocacy opportunities, contact NACDS director of grassroots and advocacy Heidi Ecker at (703) 549-3001.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?